Study of Adding Entecavir to Current Lamivudine Therapy in HIV and HBV Co-Infected Patients

Phase 2

Completed

• Conditions: Hepatitis B

• Registration Number: NCT00051038
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this clinical research study is to assess the safety and effectiveness of entecavir, when being added to lamivudine, in the treatment of adults with chronic hepatitis B infection who are co-infected with HIV.

Detailed Description

Not available

Study Timeline

• Study Start: 2002-09
• Study First Submitted: 2002-12-31
• Study First Submitted QC: 2003-01-02
• Study First Posted: 2003-01-03
• Primary Completion: 2005-10
• Study Completion: 2005-10
• Status Verified: 2007-08
• Disposition First Submitted: 2010-01-29
• Disposition First Submitted QC: 2010-01-29
• Disposition First Posted: 2010-02-02
• Last Update Submitted: 2011-04-07
• Last Update Posted: 2011-04-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Pittsburgh, Pennsylvania, United States